Keyphrases
Antibody Targeting
11%
Antiproliferative Activity
8%
Apoptosis
8%
Cell Proliferation
17%
Cell Viability
6%
Cell-based
7%
Children's Oncology Group
6%
Clinical Response
6%
Clinical Trials
7%
Cyclophosphamide
7%
Cytotoxicity
10%
Difluoromethylornithine
39%
Event-free Survival
10%
Ewing Sarcoma
11%
Guided Therapy
11%
High-risk Neuroblastoma
40%
IC50
7%
Induced Apoptosis
15%
Inhibit Tumor
13%
Maintenance Therapy
9%
Medulloblastoma
17%
Multiple Antibodies
11%
Neuroblastoma
87%
Neuroblastoma Cell Line
15%
Neuroblastoma Cells
35%
Nifurtimox
18%
Novel Therapeutics
6%
Ornithine Decarboxylase
12%
Overall Survival
9%
Pediatric Oncology
6%
Pediatric Patients
7%
Phase I Trial
11%
Phase II Trial
13%
Polyamines
14%
Pro-apoptotic
7%
Proliferation Apoptosis
11%
Recombinant
6%
Refractory Neuroblastoma
24%
Relapsed or Refractory
32%
Sirolimus
7%
Survival Outcomes
7%
Synergize
11%
Therapeutic Potential
7%
Topotecan
7%
Tumor
19%
Tumor Growth
14%
Tumor Inhibition
7%
Tumor mutation Burden
11%
Tumorigenesis
6%
Xenograft
6%
Medicine and Dentistry
Adverse Event
11%
Antiangiogenic Therapy
5%
Atrium
5%
Biopsy Technique
5%
Calcifediol
5%
Carcinogenesis
6%
Cell Death
7%
Cell Proliferation
7%
Cell Surface
6%
Chemotherapy
5%
Childhood Cancer
10%
Circulating Tumor Cell
5%
Clinical Trial
7%
Cyclophosphamide
7%
Cytotoxicity
6%
Diseases
19%
Drug Repositioning
5%
Eflornithine
42%
Event Free Survival
8%
Ganglioneuroblastoma
100%
Gene Expression Profiling
7%
Immune Evasion
5%
Immunocompetent Cell
5%
Immunotherapy
8%
In Vitro
11%
Long Term Survival
7%
Maintenance Therapy
9%
Medulloblastoma
5%
Neoplasm
35%
Neuroblastoma Cell
14%
Neuroblastoma Cell Line
7%
Nifurtimox
18%
Oncology
6%
Ornithine Decarboxylase
5%
Overall Survival
8%
Patient with Neuroblastoma
8%
Pediatrics
10%
Pediatrics Patient
7%
Phase II Trials
12%
Polyamine
11%
Polyclonal Antibody
5%
Small-Cell Carcinoma
5%
Solid Malignant Neoplasm
7%
Specific Tumor
11%
Stress Activated Protein Kinase
5%
Tolcapone
5%
Topotecan
7%
Tumor Progression
13%
Vimentin
5%
Xenograft
14%